
Gareth O Griffiths

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6979162/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Accuracy of rapid point-of-care antibody test in patients with suspected or confirmed COVID-19. Journal of Infection, 2022, 84, 94-118.	1.7	1
2	An Open Label, Adaptive, Phase 1 Trial of Highâ€Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARSâ€CoVâ€2. Clinical Pharmacology and Therapeutics, 2022, 111, 585-594.	2.3	14
3	Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT. Health Technology Assessment, 2021, 25, 1-144.	1.3	2
4	AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. Trials, 2021, 22, 487.	0.7	14
5	Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of Antimicrobial Chemotherapy, 2021, 76, 3286-3295.	1.3	84
6	Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer, 2021, 153, 153-161.	1.3	8
7	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 691.	0.7	62
8	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology,the, 2020, 7, e746-e755.	2.2	21
9	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Medical Research Methodology, 2020, 20, 113.	1.4	37
10	Patient-reported outcome measures for monitoring primary care patients with depression (PROMDEP): study protocol for a randomised controlled trial. Trials, 2020, 21, 441.	0.7	8
11	REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial. Trials, 2020, 21, 419.	0.7	11
12	Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. Trials, 2020, 21, 478.	0.7	54
13	AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Trials, 2020, 21, 544.	0.7	23
14	A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in firstâ€line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU International, 2020, 126, 292-299.	1.3	4
15	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
16	Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study. Trials, 2020, 21, 304.	0.7	24
17	The Active Brains Digital Intervention to Reduce Cognitive Decline in Older Adults: Protocol for a Feasibility Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e18929.	0.5	2
18	HATRIC: a study of Pelargonium sidoides root extract EPs®7630 (Kaloba®) for the treatment of acute cough due to lower respiratory tract infection in adults—study protocol for a double blind, placebo-controlled randomised feasibility trial. Pilot and Feasibility Studies, 2019, 5, 98.	0.5	5

GARETH O GRIFFITHS

#	Article	IF	CITATIONS
19	BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract. PLoS ONE, 2019, 14, e0210785.	1.1	6
20	Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study. Trials, 2018, 19, 419.	0.7	9
21	A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer, 2018, 119, 697-706.	2.9	26
22	NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer, 2017, 74, 38-46.	1.3	37
23	Uva-ursi extract and ibuprofen as alternative treatments of adult female urinary tract infection (ATAFUTI): study protocol for a randomised controlled trial. Trials, 2017, 18, 421.	0.7	11
24	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	0.8	18
25	Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic) Tj ETQq1 1 0.78431	4 r gB T /Ov	ver ba ck 10 Tf
26	Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. Journal of Clinical Oncology, 2016, 34, 488-494.	0.8	138
27	SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma. European Urology, 2015, 67, 599-602.	0.9	29
28	NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer, 2015, 15, 48.	1.1	29
29	Health-Related Quality of Life in SCALOP, aÂRandomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 810-818.	0.4	32
30	Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2014, 15, 1361-1368.	5.1	85
31	Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials, 2014, 15, 402.	0.7	19
32	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncology, The, 2013, 14, 627-637.	5.1	346
33	SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer, 2011, 11, 466.	1.1	43
34	International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial. Journal of Clinical Oncology, 2011, 29, 2171-2177.	0.8	804
35	FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer, 2009, 9, 355.	1.1	52